Medical Condition News

RSS

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG.

1 Nov 2010

Mechanism of rogue cell killer discovered

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

1 Nov 2010

UCSD announces agreement with PHP to develop UC San Diego Proton Therapy and Research Center

Building on a plan announced in September of 2007, UC San Diego Health Sciences and the Department of Radiation Oncology are pleased to announce an agreement with Proton Health Partners, LLC (PHP) to plan, develop, and operate The UC San Diego Proton Therapy and Research Center.

1 Nov 2010

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from the University of Texas Southwestern and Fox Chase Cancer Center, will be presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego from October 31 to November 4.

1 Nov 2010

Cell Therapeutics announces submission of MAA to European Medicines Agency for Pixuvri

Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.

1 Nov 2010

NeurAxon’s NXN-188 compound effective for acute migraine treatment

NeurAxon, Inc., announced today Phase 2 clinical study results for NXN-188, a novel, first-in-class treatment with the potential to raise the current standard of care in acute migraine.

1 Nov 2010

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Scientists from the UK and Australia have seen the human immune system's assassin a protein called perforin in action for the first time. The UK team, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Wellcome Trust, is based at Birkbeck College where they used powerful electron microscopes to study the mechanism that perforin uses to punch holes in rogue cells.

1 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

Philips launches HFO Oncology Configuration for radiation therapy

Royal Philips Electronics today introduced the Philips Panorama High Field Open (HFO) Oncology Configuration for radiation therapy, a magnetic resonance (MR) imaging solution for dedicated oncology use, at this year's American Society for Therapeutic Radiology and Oncology (ASTRO) in San Diego, CA.

From Philips Healthcare 1 Nov 2010

FDA approves Afinitor drug for tuberous sclerosis complex

The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.

1 Nov 2010

Gottlieb Hospital nurse raises $2,000 to fight breast cancer

Theresa Oles runs for her life every day. This fall, the nurse anesthesist who goes running to unwind, is pounding the pavement to fight breast cancer in the Chicago Breast Cancer Network of Strength marathon.

1 Nov 2010

The Melting Pot joins St. Jude in seventh annual Thanks and Giving campaign

The Melting Pot Restaurants join St. Jude Children's Research Hospital in the seventh annual Thanks and Giving campaign from Nov. 1 - Dec. 4, to give thanks for the healthy kids in your life, and give to those who are not by donating to cancer research.

30 Oct 2010

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

OptiNose Inc. announced the results from an analysis comparing the Phase II clinical trial obtained with its novel delivery technology to that of other formulations. The analysis suggests rapid absorption rate alone may not explain the efficacy in migraines treated with sumatriptan delivered with the Company's novel bi-directional technology. The results will be presented at the 2nd European Headache and Migraine Trust International on 28th of October 2010.

30 Oct 2010

New Specialist Library offers treatment for eating disorders

Eating Disorder Hope, a respected independent resource for individuals suffering from anorexia, bulimia, binge eating and other body image and eating disorders, has expanded its Eating Disorder Specialist Library to further help sufferers of anorexia, bulimia and binge eating disorder find treatment options.

30 Oct 2010

National Conference to educate breast cancer patients about personal health

Leading breast cancer experts and survivors will present at this weekend's Body, Mind, Spirit 2010: National Conference for Young Women Living with Breast Cancer. Presented by the Canadian Breast Cancer Network and co-presenter the Canadian Breast Cancer Foundation, this conference hosts young women with breast cancer to educate them in all aspects of their cancer journey.

30 Oct 2010

UK HealthCare transplant recipient wins at 2010 U.S. Transplant Games

One transplant recipient from UK HealthCare, Dan Gutenson of Stanford, Ky., joined the 36 other members of "Team Kentucky" in Madison, Wisconsin for the 2010 U.S. Transplant Games this past summer. Gutenson, who received his kidney transplant in Sept. 2009, suffered from polycystic disease and received a kidney from a living donor in the church he pastors in Lincoln County, Ky.

30 Oct 2010

Researchers enforce to review current regulation on food advertisements

The researchers, in partnership with the Cancer Council, Australia, studied 12,618 food advertisements from 11 countries and found that 67 per cent endorsed unhealthy food. The research builds on a previous study at Liverpool which revealed that children would consume twice as many calories from snacks after watching food adverts compared to after viewing advertising for toys and games.

30 Oct 2010

Health Canada approves PRADAX for preventing stroke in AF patients

Health Canada, the Canadian health authority, has approved PRADAX™ (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate, marking the second approval of this new oral anticoagulant following the recent marketing authorisation by the US Food and Drug Administration (FDA).

30 Oct 2010

Former Member of Congress joins Lung Cancer Alliance

Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors. Oxley, a former Member of Congress, joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.

30 Oct 2010

Brigham and Women's, and UI Hospitals and Clinics begin certification for SynCardia artificial heart implantation

SynCardia Systems, Inc. announced today that Brigham and Women's Hospital in Boston, and University of Iowa (UI) Hospitals and Clinics in Iowa City, Iowa, have begun certification to implant the SynCardia temporary Total Artificial Heart. Brigham and Women's will complete Phase I of certification on Nov. 1 & 2, and UI Hospitals and Clinics completed Phase I on Oct. 21 & 22.

30 Oct 2010

Medical Condition News

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Mechanism of rogue cell killer discovered

UCSD announces agreement with PHP to develop UC San Diego Proton Therapy and Research Center

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

Cell Therapeutics announces submission of MAA to European Medicines Agency for Pixuvri

NeurAxon’s NXN-188 compound effective for acute migraine treatment

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Philips launches HFO Oncology Configuration for radiation therapy

FDA approves Afinitor drug for tuberous sclerosis complex

Gottlieb Hospital nurse raises $2,000 to fight breast cancer

The Melting Pot joins St. Jude in seventh annual Thanks and Giving campaign

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

New Specialist Library offers treatment for eating disorders

National Conference to educate breast cancer patients about personal health

UK HealthCare transplant recipient wins at 2010 U.S. Transplant Games

Researchers enforce to review current regulation on food advertisements

Health Canada approves PRADAX for preventing stroke in AF patients

Former Member of Congress joins Lung Cancer Alliance

Brigham and Women's, and UI Hospitals and Clinics begin certification for SynCardia artificial heart implantation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News